Adaptin Bio (APTN) Liabilities and Shareholders Equity (2022 - 2026)

Adaptin Bio has disclosed Liabilities and Shareholders Equity across 5 years of filings, most recently posting $706117.0 for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 75.26% year-over-year to $706117.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 28.23% YoY) and the FY2025 annual result came in at $619159.0, up 158.61% from the prior year.
• Liabilities and Shareholders Equity rose to $706117.0 in Q1 2026, from $619159.0 in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.9 million in Q1 2025 and bottomed at $322.0 in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $119957.5 (2022), against an average of $588590.7.
• Year-over-year, Liabilities and Shareholders Equity jumped 750953.68% in 2025 and tumbled 75.26% in 2026.
• Adaptin Bio's Liabilities and Shareholders Equity stood at $500.0 in 2022, then slipped by 24.0% to $380.0 in 2023, then soared by 62903.95% to $239415.0 in 2024, then jumped by 158.61% to $619159.0 in 2025, then grew by 14.04% to $706117.0 in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $706117.0, $619159.0, and $979474.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.